BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, December 12, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Jiangsu Hengrui Medicine and collaborators patent vasopressin V2 receptor antagonists
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cardiovascular
Jiangsu Hengrui Medicine and collaborators patent vasopressin V2 receptor antagonists
Sep. 8, 2022
No Comments
Jiangsu Hengrui Medicine Co. Ltd. has described prodrugs of tolvaptan acting as vasopressin V2 receptor antagonists.
BioWorld Science
Cardiovascular
Patents
